NeoGenomics (NASDAQ:NEO) PT Raised to $64.00 at Morgan Stanley
Several other research firms also recently weighed in on NEO. Craig Hallum upped their price target on NeoGenomics from $50.00 to $65.00 and gave the stock a buy rating in a research note on Thursday, February 25th. Zacks Investment Research cut NeoGenomics from a hold rating to a sell rating in a report on Wednesday. BTIG Research started coverage on NeoGenomics in a report on Friday, December 11th. They set a buy rating on the stock. Raymond James cut NeoGenomics from an outperform rating to a market perform rating in a report on Thursday, February 25th. They noted that the move was a valuation call. Finally, SVB Leerink upped their price objective on NeoGenomics from $50.00 to $60.00 and gave the stock an outperform rating in a report on Friday, January 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $48.63.
NEO stock opened at $43.25 on Wednesday. NeoGenomics has a 1-year low of $20.47 and a 1-year high of $61.57. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.54 and a quick ratio of 6.22. The company has a market capitalization of $5.06 billion, a price-to-earnings ratio of -1,441.19 and a beta of 0.79. The business has a 50 day simple moving average of $54.60 and a two-hundred day simple moving average of $46.32.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Wednesday, February 24th. The medical research company reported $0.14 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.08. NeoGenomics had a positive return on equity of 0.71% and a negative net margin of 1.16%. The business had revenue of $126.00 million during the quarter, compared to the consensus estimate of $123.45 million. During the same period in the prior year, the company posted $0.06 EPS. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. Sell-side analysts anticipate that NeoGenomics will post -0.01 EPS for the current fiscal year.
In other NeoGenomics news, insider Lawrence Martin Weiss sold 20,200 shares of the business’s stock in a transaction dated Monday, December 14th. The shares were sold at an average price of $51.06, for a total value of $1,031,412.00. Following the completion of the sale, the insider now directly owns 61,717 shares of the company’s stock, valued at approximately $3,151,270.02. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Steven C. Jones sold 25,000 shares of the business’s stock in a transaction dated Monday, December 14th. The shares were sold at an average price of $51.67, for a total transaction of $1,291,750.00. Following the completion of the sale, the director now directly owns 72,932 shares of the company’s stock, valued at $3,768,396.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 210,200 shares of company stock valued at $10,390,512. 6.50% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in NeoGenomics in the 4th quarter valued at about $47,000. KBC Group NV bought a new stake in shares of NeoGenomics in the 4th quarter valued at about $56,000. Capital Asset Advisory Services LLC bought a new stake in shares of NeoGenomics in the 4th quarter valued at about $60,000. FinTrust Capital Advisors LLC raised its holdings in shares of NeoGenomics by 27.0% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 1,270 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 270 shares in the last quarter. Finally, RWM Asset Management LLC bought a new stake in shares of NeoGenomics in the 4th quarter valued at about $73,000. 91.06% of the stock is owned by institutional investors.
About NeoGenomics
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Article: Benefits of owning preferred stock
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source